ID: ALA4280062

Max Phase: Preclinical

Molecular Formula: C22H22O4

Molecular Weight: 350.41

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc(/C=C2\CCC/C(=C\c3cccc(O)c3)C2=O)cc1OC

Standard InChI:  InChI=1S/C22H22O4/c1-25-20-10-9-16(14-21(20)26-2)12-18-7-4-6-17(22(18)24)11-15-5-3-8-19(23)13-15/h3,5,8-14,23H,4,6-7H2,1-2H3/b17-11+,18-12+

Standard InChI Key:  BFRAXBYZLYVSHD-JYFOCSDGSA-N

Associated Targets(Human)

SW-620 52400 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A549 127892 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HT-1080 3966 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MCF7 126967 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

NHDF 1164 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 350.41Molecular Weight (Monoisotopic): 350.1518AlogP: 4.63#Rotatable Bonds: 4
Polar Surface Area: 55.76Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 9.40CX Basic pKa: CX LogP: 4.98CX LogD: 4.97
Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.82Np Likeness Score: 0.03

References

1. Leong SW, Chia SL, Abas F, Yusoff K..  (2018)  Asymmetrical meta-methoxylated diarylpentanoids: Rational design, synthesis and anti-cancer evaluation in-vitro.,  157  [PMID:30138803] [10.1016/j.ejmech.2018.08.039]

Source